Skip to main content

Pharma RSS Digest - 2026-06-09

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The 48-hour window was dominated by company-specific catalysts with limited cross-sector themes. In oncology, OriCell's NMPA clearance for a confirmatory Phase II trial positions China as a potential leader in solid-tumor CAR-T—an area where Western developers have historically struggled—while Dayspring Pharma's positive Phase II readout in androgenetic alopecia underscores continued interest in reformulating established generics to address safety and adherence limitations. Medical device activity centers on a BD recall and Gore's CE Mark expansion for its venous stent, neither directly competitive with the pharmaceutical developments. Novo Nordisk's REIMAGINE data reinforces the amylin-GLP-1 combination thesis but lacks the novelty of a new mechanism.

Key Developments​

OriCell's GPC3 CAR-T Advances to Confirmatory Phase II in Late-Line Liver Cancer
OriCell received NMPA clearance for a confirmatory Phase II trial of Ori-C101, the first GPC3-directed immune cell therapy globally to reach this stage. Phase I BEACON data showed a 50% overall objective response rate, with 100% ORR at the highest dose cohort and median overall survival of 21.4 months versus approximately 10.6 months historically. The randomized trial will enroll GPC3-positive hepatocellular carcinoma patients who have failed at least two prior lines of therapy including both TKIs and ICIs. GPC3 is overexpressed in over 70% of HCC cases and also in gastric, lung squamous cell, and ovarian clear cell cancers, providing a potential pathway for indication expansion. What to watch: Phase II enrollment进度 and whether OriCell outlines a path toward FDA or other ex-China regulatory submissions.

OriCell's GPC3 CAR-T fda approval update

Dayspring Pharma's CG2001 Topical Foam Meets Phase II Endpoint in Androgenetic Alopecia
Dayspring Pharma announced positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001, a fixed-dose topical foam combining 5% minoxidil with 0.075% finasteride. At Week 24, the twice-daily arm achieved a statistically significant 28.17 hairs/cm² increase in target area hair count versus 7.68 hairs/cm² for placebo (p=0.006), with no sex-related adverse events reported. The company is now engaging regulators to define Phase III development plans. The foam formulation aims to improve local follicular delivery while reducing the systemic exposure associated with oral finasteride, which carries known risks of sexual dysfunction. What to watch: Phase III trial design, including dosing arms, size, and whether regulators accept hair count as a pivotal endpoint.

Dayspring Pharma clinical trial update

Watchlist​

  • BD Issues Nationwide Recall for ChloraPrep™ and FREPP™ Applicators – Two lots of applicators are being recalled due to potential fungal contamination with Aspergillus penicillioides; no adverse events reported as of the announcement, though contamination poses serious infection risk if introduced during catheter placement or surgery. [link]
  • Gore VIABAHN FORTEGRA Venous Stent Receives CE Mark (MDR) Approval – The stent is now approved in Europe for symptomatic IVC and iliofemoral venous outflow obstruction, with a prospective trial showing 81% pain improvement and 83.4% primary patency at 12 months; US FDA approval had previously been obtained. [link]
  • Novo Nordisk's CagriSema REIMAGINE Program Data at ADA 2026 – Phase III results showed significant HbA1c and weight reductions with the amylin-GLP-1 combination in type 2 diabetes; full REIMAGINE 2 data (n=2,713) and safety details were not fully included in available summaries. [link]